Evidence map›Paper›PMID 39392205›Full record

ArticleAnalytical chemistry2024

An Accurate and Fast

Jiayi Li, Fu Chen, Deyi Zhang, Yan Wang, Darby Kozak, Kang Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytical chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jiayi LiDivision of Pharmaceutical Quality Research II, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Fu ChenDepartment of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742, United States.
Deyi ZhangDivision of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drug, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Yan WangDivision of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drug, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Darby KozakDivision of Therapeutic Performance I, Office of Research and Standards, Office of Generic Drug, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland 20993, United States.
Kang ChenDivision of Pharmaceutical Quality Research II, Office of Pharmaceutical Quality Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993, United States.ORCID 0000-0003-0276-2474

Funding

Intramural FDA HHS FD999999
6 · The paper itself

Abstract

Chemically modified nucleic acid molecules have been developed as oligonucleotide therapeutics, and its assay is critical in quality assurance. The common DNA/RNA quantification method using UV-260 nm can lack accuracy because of structure modifications and the possible formation of higher-order structure (HOS). Additionally, process-associated water and counterions affect the accuracy in gravimetric analysis. Thus, to improve accuracy, efficiency, and flexibility, in this work a fast (<1 h) externally referenced

Indexed as

Magnetic Resonance SpectroscopyOligonucleotidesMorpholinosMorpholinosOligonucleotides

Identifiers

PMID39392205
PMCPMC12379111

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.